TG Therapeutics Inc

Despite neutral overbought readings, TCEHY.TO remains in a Stage 2 advance fueled by an active Lockout Rally pattern, indicating sustained institutional demand. Price is holding just above rising EMAs, with pullbacks into the $53.50–$54.00 confluence offering structurally supportive entry. Typical timing filters are overridden by Lockout Rally dynamics, favoring immediate engagement. Key resistance lies near $56.00, where exhaustion signals should be monitored. Overall, initiating now aligns with continuation participation while guarding against a break below EMA support.

• ↑Q2 U.S. net revenue $228M (+64% YoY) shows strong demand.
• ↑Raised FY26 revenue guidance to $890–905M on BrionV growth.
• ↓Negative earnings yield and poor book-to-price indicate valuation risk.